CBARP: A Potential Drug Target for Chronic Pain Conditions (G255057)

Target Name: CBARP

NCBI ID: G255057

CBARP

CBARP: A Potential Drug Target for Chronic Pain Conditions

CBARP (CBARP variant 2) is a protein that is expressed in the brain and is known for its role in the regulation of pain signaling. It is a potential drug target (or biomarker) for the treatment of chronic pain conditions such as migraines, fibromyalgia, and neuroimmune disorders.

CBARP is a transmembrane protein that is composed of four intracellular domains: an N-terminus, a catalytic center, a regulatory region, and a C-terminus. It is expressed in the brain and is involved in the regulation of pain signaling pathways.

The N-terminus of CBARP is the most well-studied, as it contains a putative GPCR (G protein-coupled receptor) that is involved in the regulation of pain signaling. The GPCR is thought to play a role in the perception of pain by modulating the release of neurotransmitters such as serotonin and dopamine.

The catalytic center of CBARP is known as the \"serotonin transporter\" and is involved in the regulation of serotonin signaling. It is thought to play a role in the regulation of pain perception by modulating the levels of serotonin in the brain.

The regulatory region of CBARP is involved in the regulation of its own expression and function. It is known to play a role in the regulation of cell survival and has been shown to be involved in the regulation of neurogenesis.

The C-terminus of CBARP is the least well-studied, but is known to be involved in the regulation of pain signaling. It is thought to play a role in the regulation of pain perception by modulating the release of neurotransmitters such as calcitonin.

CBARP is a potential drug target (or biomarker) for the treatment of chronic pain conditions such as migraines, fibromyalgia, and neuroimmune disorders. Because it is involved in the regulation of pain signaling pathways, it is thought to be a promising target for the treatment of chronic pain conditions. Additionally, because it is expressed in the brain, it is also a potential target for the treatment of neurodegenerative disorders.

In conclusion, CBARP (CBARP variant 2) is a protein that is involved in the regulation of pain signaling pathways and is a potential drug target (or biomarker) for the treatment of chronic pain conditions. Further research is needed to fully understand its role in pain regulation and its potential as a therapeutic target.

Protein Name: CACN Subunit Beta Associated Regulatory Protein

Functions: Negatively regulates voltage-gated calcium channels by preventing the interaction between their alpha and beta subunits. Thereby, negatively regulates calcium channels activity at the plasma membrane and indirectly inhibits calcium-regulated exocytosis

The "CBARP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBARP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets